SHANGHAI – Jiangsu Hengrui Medicine Co. Ltd. is one of China’s most profitable non-state-run pharmaceutical firms focused on generics. With a market cap of $14.2 billion, last year Jiangsu Hengrui raked in revenues of $1.4 billion with a net profit of $327 million. But Chairman Piaoyang Sun saw the writing on the wall a few years back and has been preparing his company for an innovative future, one in which the U.S. plays a key role.